ASH 2018 | Analyzing AML: novel therapies in review

Name: Analyzing AML: novel therapies in review
Uploaded: 2018-12-01T00:00:00.000Z
Duration: 2 min 25 s
Description: Farhad Ravandi-Kashani, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, shares key highlights, including trials, future outlooks, and progressions in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Farhad Ravandi • 1 Dec 2018

ASH 2018

Acute Myeloid Leukemia Leukemia Gilteritinib Glasdegib Venetoclax

Farhad Ravandi-Kashani, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, shares key highlights, including trials, future outlooks, and progressions in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.